Cyxone has entered into a research collaboration with a renowned British research group in Glasgow with the aim of conducting an exploratory phase II study with rabeximod in rheumatoid arthritis patients. BioStock reached out to CEO Carl-Magnus Högerkorp, who highlights the research group's collaboration with the universities of Birmingham, Newcastle, and Oxford in the field.

Read the full interview with Carl-Magnus Högerkorp at biostock.se:

https://www.biostock.se/en/2024/03/cyxone-comments-on-the-clinical-collaboration-in-the-uk/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

https://news.cision.com/cyxone/r/biostock-cyxone-comments-on-the-clinical-collaboration-in-the-uk,c3954307

(c) 2024 Cision. All rights reserved., source Press Releases - English